PFG
NBIX icon

PAX Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

PAX Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$387K Sell
2,934
-401
-12% -$53.2K 0.07% 139
2025
Q4 		$473K Sell
3,335
-1,143
-26% -$166K 0.08% 128
2025
Q3 		$629K Sell
4,478
-943
-17% -$128K 0.11% 122
2025
Q2 		$681K Sell
5,421
-2,517
-32% -$289K 0.13% 118
2025
Q1 		$878K Buy
7,938
+11
+0.1% +$1.39K 0.16% 113
2024
Q4 		$1.08M Sell
7,927
-281
-3% -$34.8K 0.19% 96
2024
Q3 		$946K Sell
8,208
-605
-7% -$82.9K 0.17% 107
2024
Q2 		$1.21M Sell
8,813
-1,134
-11% -$156K 0.24% 78
2024
Q1 		$1.37M Sell
9,947
-432
-4% -$59K 0.28% 72
2023
Q4 		$1.4M Sell
10,379
-1,202
-10% -$138K 0.29% 63
2023
Q3 		$1.3M Sell
11,581
-5,891
-34% -$620K 0.3% 62
2023
Q2 		$1.65M Buy
17,472
+1,217
+7% +$119K 0.37% 49
2023
Q1 		$1.65M Buy
+16,255
New +$1.69M 0.39% 46

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAX Financial Group's NBIX Position: Q1 2026 in Review

PAX Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 12% in Q1 2026, selling an estimated $53.2K and leaving 2,934 shares worth $387K. The position accounts for 0.07% of the portfolio, ranked #139.

PAX Financial Group first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.65M in Q2 2023. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • PAX Financial Group held 2,934 shares of Neurocrine Biosciences worth $387K as of Q1 2026.
  • PAX Financial Group sold 401 Neurocrine Biosciences shares in Q1 2026, an estimated $53.2K.
  • Neurocrine Biosciences made up 0.07% of PAX Financial Group's portfolio in Q1 2026, its #139 holding.
  • PAX Financial Group first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
  • PAX Financial Group's Neurocrine Biosciences position peaked at $1.65M in Q2 2023.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on PAX Financial Group's 13F filing for Q1 2026, filed 27 Apr 2026.